Leqembi Coverage Expansion: US Medicare Head Promises Light Touch On Registry

The US Medicare agency is telling Congress that all Alzheimer’s patients covered by the approved indication will have access to the beta amyloid therapy Leqembi once it is converted from Accelerated Approval to traditional approval.

A registry required for “fully” approved beta amyloid therapies under a coverage policy adopted by the Centers for Medicare & Medicaid Services in 2022 “in no way limits people from getting access to the drug,” CMS Administrator Chiquita